Research
Hormonal
Tirzepatide led to a greater reduction in median triglyceride levels compared with semaglutide.
Tirzepatide may be preferred for patients needing significant triglyceride reduction.
StrongSupportsmedium confidence
Tirzepatide led to a greater reduction in median triglyceride levels compared with semaglutide.
Why this rating
The study is a retrospective chart review involving a specific patient cohort.
Source
Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients.
Omar El Khatib et al. · Experimental and Clinical Transplantation · 2026
DOI 10.6002/ect.2025.0180
cohort · n=73
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Both tirzepatide and semaglutide significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels in solid-organ transplant recipients.Strong
- Adverse events were more frequent in the semaglutide group, including gastrointestinal intolerance and infections.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →